Spruce Biosciences Q1 net loss $12.3M; cash $54.1M (Mar 31), $107.3M (Apr 30)

SPRUCE BIOSCIENCES, INC.

Net loss of $12.3M ($8.94 per share) for Q1 2026; R&D expenses $7.6M, G&A $4.4M.
Cash $54.1M at March 31, 2026; preliminary cash $107.3M at April 30, 2026; runway into H2 2027.
Closed $69.0M diluted public offering in April 2026; secured up to $50M term loan from Avenue Capital (Tranche 1: $15M funded).
BLA submission for TA-ERT (MPS IIIB) on track for Q4 2026; long-term data showed durable HS reduction and cognitive stabilization.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001193125-26-220648

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.